IDiyas

For the Inventor, By the Inventor

Lindenhurst, IL, United States of America

Joseph F Dellaria, Jr

USPTO Granted Patents = 23

Average Co-Inventor Count = 3.2

ph-index = 7

Forward Citations = 223(Granted Patents)


Company Filing History:

goldMedal23 out of 4,177 
 
Abbott Laboratories Corporation
 patents

Years Active: 1991-2001

Loading Chart...
23 patents (USPTO):Explore Patents
1. 6294573 - Reverse hydroxamate inhibitors of matrix metalloproteinases (2001-09-25),
2. 6207701 - Urokinase inhibitors (2001-03-27),
3. 5776984 - Prostaglandin synthase-2 inhibitors (1998-07-07),
4. 5681842 - Prostaglandin synthase-2 inhibitors (1997-10-28),
5. 5516795 - Heteroatom substituted propanyl derivatives having 5-lipoxygenase (1996-05-14),
6. 5514702 - Arylamidoalkyl-N-hydroxyurea compounds having lipoxygenase inhibitory (1996-05-07),
7. 5484786 - Pyran-4-ylmethyl substituted arylalkylaryl-, arylalkenylylaryl-, and (1996-01-16),
8. 5475009 - 1, 2-dialkoxyethanes as 5-lipoxygenase inhibitors (1995-12-12),
9. 5459150 - Indole derivatives which inhibit leukotriene biosynthesis (1995-10-17),
10. 5446062 - ((4-alkoxypyran-4-yl) substituted) ether, arylalkyl-, arylalkenyl-, and (1995-08-29),
11. 5446055 - Polyether naphthalenic lignan lactones as inhibitors of 5-lipoxygenase (1995-08-29),
12. 5432194 - (4-alkoxypyran-4-yl) substituted arylalkylaryl-, aryalkenylaryl-, and (1995-07-11),
13. 5426111 - [Alkoxy-, alkenyloxy-, alkynyloxy-, and phenylmethyloxyalkoxycycloalkyl (1995-06-20),
14. 5407959 - (Trans-1,4-dialkoxycyclohexyl) substituted (1995-04-18),
15. 5354865 - Phenylmethyl derivatives having lipoxygenase inhibitory activity (1994-10-11),

Title: Joseph F. Dellaria, Jr.: Innovator in Matrix Metalloproteinase Inhibitors

Introduction

Joseph F. Dellaria, Jr. is a notable inventor based in Lindenhurst, IL, with an impressive portfolio of 23 patents. His work primarily focuses on advancing pharmaceutical compounds, particularly in the realm of matrix metalloproteinase inhibitors.

Latest Patents

Among his latest patents, Dellaria has developed reverse hydroxamate inhibitors of matrix metalloproteinases, which are crucial in the treatment of various diseases. Additionally, he has created urokinase inhibitors, further demonstrating his innovative capabilities in medicinal chemistry.

Career Highlights

Dellaria is affiliated with Abbott Laboratories Corporation, where he continues to contribute to advancements in drug development and research. His expertise and groundbreaking inventions have significantly impacted the pharmaceutical industry.

Collaborations

Throughout his career, Dellaria has collaborated with distinguished colleagues such as Dee W. Brooks and Anwer Basha. Their collective efforts have led to the successful development and patenting of new compounds which may provide therapeutic benefits in treating complex health conditions.

Conclusion

Joseph F. Dellaria, Jr. stands out as a prominent inventor in the field of medicinal chemistry, with a robust patent portfolio and impactful innovations. His contributions to matrix metalloproteinase inhibitors highlight the importance of collaboration and discovery in advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…